



Republic of the Philippines
Department of Health
OFFICE OF THE SECRETARY

DEPARTMENT MEMORANDUM

NO. 2015- 0110

TO: ALL DOH REGIONAL OFFICE DIRECTORS, DIRECTORS AND CHIEFS OF HOSPITALS WITH DOTS TREATMENT FACILITIES, LOCAL GOVERNMENT UNITS, PROVINCIAL HEALTH OFFICES, CITY HEALTH OFFICES AND RURAL HEALTH UNITS

SUBJECT: PRODUCT RECALL ORDER OF RIFAMPICIN (RIFANID) SUSPENSION 200mg/5mL

DATE: 15 APRIL 2015


This has reference to the Product Recall Order issued by Food and Drugs Administration (FDA) on 05 March 2015 with reference no CDRR-PRO-2015-009 to the respondent, Phil Pharmawealth Inc. (PPI) on their antibiotic product, Rifampicin (Rifanid) 200mg/5mL Suspension, with batch number C30005 and Registration No. DR-XY30945, which will expire on July 2016 from three different sources, to wit:

Source	Batch No./ Exp. Date	Test	Method	Specification	Result
Dagupan Health Center	C30005/ July 2016	Assay	UV-VIS (BP2008)	90.0-110.0%	84.6% (169.23mg/5mL)
National Children's Hospital					76.2% (152.48mg/5mL)
Magsaysay Health Center					79.6% (159.17mg/5mL)

Copy of the product recall order issued to PPI, is hereto attached for your reference.

With this, your offices are hereby directed to withdraw and return to the Department of Health- Logistics Management Division (DOH-LMD) the aforementioned Anti TB drugs Kit for Children bearing the same batch number the soonest possible time.

For your information and compliance.


JANETTE LORETO-GARIN, MD, MBA-H
Secretary of Health



Republic of the Philippines
Department of Health
OFFICE OF THE SECRETARY

DEPARTMENT MEMORANDUM
NO. 2015- 0124


TO: ALL DOH REGIONAL OFFICE DIRECTORS, DIRECTORS AND CHIEFS OF TB DOTS REFERRING/ PROVIDING HOSPITALS, LOCAL GOVERNMENT UNITS, PROVINCIAL HEALTH OFFICES, CITY HEALTH OFFICES AND RURAL HEALTH UNITS

SUBJECT: AMENDMENT OF DEPARTMENT MEMORANDUM NO. 2015-0110 WHICH PROVIDES FOR THE PRODUCT RECALL ORDER OF RIFAMPICIN (RIFANID) SUSPENSION 200mg/5mL

DATE: 23 APRIL 2015

Relative to Department Memorandum No. 2015-0110 the product recall order issued by Food and Drugs Administration (FDA) pertains only to Rifampicin (Rifanid) 200mg/5mL Suspension with Batch No. C30005 which shall be withdrawn by Phil Pharmawealth Inc. (PPI) from the respective Regional Warehouses of the said medicine instead of returning the product to the Department Of Health -Logistics Management Division (LMD).

Given this, recipients of the said medicine must coordinate with Mr. Jover Francisco, RPh, NTP Drugs and Supplies Management (DSM) Coordinator, Ms. Ghenimelle Rose Pasumbal, RPh, NTP DSM Officer, Ms. Marie Kristine Padilla, RPh, NTP DSM Officer at (02)310-5713 and Ms. Lalaine Rocero, Vice President for Sales- Government Accounts of PPI at (02) 683-0053 to 57 local 169 for the return or collection of the recalled product.


JANETTE LORETO-GARIN, MD, MBA-H
Secretary of Health